On August 11, 2023, the U.S. Food and Drug Administration (FDA) approved the fixed dose combination of niraparib and abiraterone acetate (Akeega^™) plus prednisone for adult patients with deleterious or suspected deleterious BRCA variant metastatic castration-resistant prostate cancer, as determined by an FDA-approved test.

On June 20, 2023, the U.S. Food and Drug Administration approved talazoparib (Talzenna®) with enzalutamide for homologous recombination repair gene–variant metastatic, castration-resistant prostate cancer.

Compared to their non-Hispanic White counterparts, most Hispanic patients with localized prostate cancer are nearly 20% more likely to have aggressive disease, but the risk varies based on their country of origin, researchers reported in study findings published in Prostate Cancer and Prostatic Diseases. Additionally, they found that the population faces disparities in access to care, with only approximately 60% receiving appropriate treatment.

An altered HOXB13 gene may increase a patient’s risk for developing prostate cancer. The HOXB13 gene is expressed in the prostate beginning in early development and affects prostate cell proliferation and differentiation and androgen receptor regulation. When it acts as a tumor suppressor gene, HOXB13 codes for a protein that regulates cell division. However, altered copies of HOXB13 are inactivated, meaning that it does not function properly or does not produce the protein it codes for, resulting in uncontrolled cell division.

Patients with germline genetic variants that increase their risk of developing prostate cancer have a lower risk of developing lethal disease when following a healthy lifestyle, according to study findings that researchers reported in European Urology.

Caregivers spend an average of 30 hours per week caring for patients with metastatic prostate cancer, researchers reported in study findings published in the Journal of Clinical Oncology.

On August 5, 2022, the U.S. Food and Drug Administration (FDA) approved darolutamide (Nubeqa®) tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer.

Patients who take anxiety or depression medication are more likely to obtain prostate-specific antigen tests, according to study findings that researchers presented at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium.

On March 23, 2022, the U.S. Food and Drug Administration (FDA) approved lutetium lu 177 vipivotide tetraxetan (Pluvicto™) for adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR)–pathway inhibition and taxane-based chemotherapy. 

Biomarker testing is an essential tool when choosing the right treatment for many advanced solid cancers. However, tissue-based testing may take weeks to get results with a chance that not enough tissue was collected to complete the entire biomarker panel. Blood draw–based liquid biopsies may be a useful alternative to identify a tumor’s biomarker details and can be performed by testing for circulating tumor DNA (ctDNA).

Among patients with metastatic, castration-resistant prostate cancer, treatment with the experimental ¹⁷⁷Lu-PSMA-617 radiopharmaceutical, along with other standard treatments, improved survival by four months over treatment with standard therapies alone, researchers reported in the New England Journal of Medicine. The therapy targets the PMSA protein and may one day be an option when other treatments have failed.

Prostate cancer is the most common cancer among those assigned male at birth, with one in eight diagnosed during their lifetime. But with five-year survival rates of 90%, it’s also one of the most successful cancers to treat, making survivorship care even more important.

On May 27, 2021, the U.S. Food and Drug Administration (FDA) approved piflufolastat F 18 (Pylarify^®), a drug for positron-emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in patients with prostate cancer.

The Decipher genomics test, which measures activity of 22 genes among seven known cancer pathways, independently estimates patients’ risk of prostate cancer metastasis, death, and overall survival and helps identify patients most likely to benefit from hormone therapy, researchers reported in study findings published in JAMA Oncology.

On December 18, 2020, the U.S. Food and Drug Administration approved relugolix (Orgovyx^TM) as the first oral hormone therapy for use in adult patients with advanced prostate cancer. 

Combining magnetic resonance imaging (MRI) with prostate-specific antigen (PSA) testing allows clinicians to detect twice as many clinically significant prostate cancers than PSA testing alone, according to study results published in JAMA Oncology.

On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved the first oral gonadotropin-releasing hormone receptor antagonist, relugolix, (Orgovyx™) for adult patients with advanced prostate cancer. 

Nurses can now navigate patients with prostate cancer to a virtual simulation for guidance on all aspects of the disease, from screening to treatment. Plus, providers can interact with Nathan, the simulation avatar, in a clinical encounter to help improve their consultation skills when discussing screening and treatment decisions with men. The Centers for Disease Control and Prevention (CDC) released this resource after launching its popular simulation for patients with breast cancer.

On May 19, 2020, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza^®) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated, metastatic, castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.

On May 15, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib (Rubraca^®) for patients with deleterious BRCA mutation (germline or somatic)-associated, metastatic, castration-resistant prostate cancer (mCRPC) who had been treated with androgen receptor-directed therapy and taxane-based chemotherapy. 

Typically, African American men have worse outcomes from prostate cancer than their white counterparts. But according to the results of a new study in patients in the U.S. Department of Veterans Affairs (VA) health system where all patients have equal access to care, no disparities exist between the two groups—in fact, the African American men in the VA system had better outcomes than non-Hispanic whites. The findings were reported in Cancer.  

Combining a traditional 12-point biopsy with magnetic resonance imaging (MRI) improves the accuracy of prostate cancer diagnosis, according to findings from a new National Institutes of Health (NIH) study published in the New England Journal of Medicine. 

One in nine men will be diagnosed with prostate cancer, the second leading cause of death in men in the United States. Survival varies greatly depending on the disease’s severity and extent at diagnosis: five-year survival rates are near 100% for local or regional disease, but they drop to 30% for metastatic prostate cancer.

On December 16, 2019, the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi^®) for patients with metastatic castration-sensitive prostate cancer.

On September 17, 2019, the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada^TM) for patients with metastatic castration-sensitive prostate cancer. Apalutamide was initially approved in 2018 for patients with non-metastatic castration-resistant prostate cancer.

On July 30, 2019, the U.S. Food and Drug Administration (FDA) approved darolutamide (Nubeqa®) for non-metastatic castration-resistant prostate cancer.

According to researchers, only 43.8% of positive genetic variants detected in men with prostate cancer had corresponding recommendations for germline testing in National Comprehensive Cancer Network (NCCN) guidelines. The findings were published in JAMA Oncology.

Patients receiving hypofractionated external-beam radiation therapy (EBRT) for early-stage prostate cancer experienced similar outcomes and toxicities as those receiving standard radiation at lower doses over a longer period of time, the American Society for Radiation Oncology, American Society of Clinical Oncology, and American Urological Association say in a new clinical guideline.

Prostate cancer cells lacking androgen receptor (AR) expression do not respond to treatment and are more likely to grow, researchers reported in study findings published in Nature Communications. 

Nearly 20% of men with metastatic, castration-resistant prostate cancer had tumors that developed into the treatment-emergent small-cell neuroendocrine (t-SCNC) subtype, which is associated with shorter survival than other subtypes, according to findings from a study published in the Journal of Clinical Oncology.

To better understand environmental and genetic impacts associated with prostate cancer in African American men, the National Institutes of Health (NIH) began a new study, Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress (RESPOND). The research program has received more than $26 million in funding and seeks to understand why African American men have disproportionally higher rates of aggressive prostate cancer than any other racial or ethnic population.

After years of decline, the death rate trend for prostate cancer has stabilized from 2013–2015, according to the National Cancer Institute’s (NCI’s) 2018 Annual Report to the Nation on the Status of Cancer.

On July 13, 2018, the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi), for patients with castration-resistant prostate cancer.

Breakthroughs and new treatments are moving faster than ever. Getting treatments approved by the U.S. Food and Drug Administration (FDA) is crucial whenever new options are making way to patients with cancer. In February 2018, the FDA approved apalutamide for the treatment of nonmetastatic prostate cancer that continues to grow despite treatment with hormone therapy, the first FDA-approved treatment for nonmetastatic, castration-resistant prostate cancer.

On February 7, 2018, the U.S. Food and Drug Administration (FDA) approved abiraterone acetate tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC).

Taller men and those with a higher body mass index (BMI) may be at increased risk for high-grade prostate cancer and disease-related mortality, according to the results of a study published in BMC Medicine.

A new three-in-one blood test that analyzes cancer DNA in the bloodstream before and during treatment will allow providers to understand and track which patients are likely to benefit from treatment with olaparib, a PARP inhibitor. Additionally, researchers found which genetic mutations prostate cancers use to resist treatment with olaparib. The study was published in Cancer Discovery.

Technology can—at times—seem miraculous, especially as it evolves in healthcare settings. Simple technologic tools have been able to lower costs, increase efficiency, minimize delays in treatment times, and even provide new, lifesaving procedures for cancer treatment.

Men younger than 65 years who sleep less than six hours per night have an increased risk of death from prostate cancer, according to the results of a study presented at the American Association for Cancer Research 2017 annual meeting.

The U.S. Preventive Services Task Force (USPSTF) has issued new draft revisions for prostate cancer screening guidelines. In the draft, the USPSTF has changed its previous stance on prostate-specific antigen (PSA) screening tests for men aged 55–69. The drafted guidelines now recommend PSA screening tests for men aged 55–69 based on individual assessment. The USPSTF has upgraded its recommendation from D to C, encouraging physicians to discuss with their patients whether PSA testing is right for them. The USPSTF still recommends against PSA screening tests in patients aged 70 or older.